logo
Ritz Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know

Ritz Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know

Yahoo2 days ago
Ritz Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know originally appeared on Parade.
Product recalls are never good news. But when they happen, it's on us as consumers to check our kitchens and make sure the foods we're eating aren't part of an affected batch. Recalls can be issued for all kinds of reasons—but faulty packaging, contamination or missing ingredients on a label are some of the most common ones.
On July 8, Mondelēz Global LLC announced a voluntary recall of four carton sizes of RITZ Peanut Butter Cracker Sandwiches. The affected products were made in the U.S. and sold nationwide.According to the FDA notice, the recall includes 8-pack, 20-pack and 40-pack cartons of RITZ Peanut Butter Cracker Sandwiches, as well as the 20-pack RITZ Filled Cracker Sandwich Variety Pack. The issue? Some individually wrapped packs may be mislabeled as the Cheese variety, even though they actually contain the Peanut Butter variety.
It's important to note that anyone with a peanut allergy or severe sensitivity could be at risk of a serious—or even life-threatening—allergic reaction if they consume these products. However, the FDA clarified that all affected outer cartons are labeled correctly and include an allergen advisory stating the product 'contains peanuts.'
To help you identify the products at home, you can find full product descriptions, 'Best When Used By' dates and UPC codes here, as well as affected product images here. You can also locate a breakdown of what the product info grid might look like on the incorrectly labeled individually wrapped packages here.According to the notice, this is a precautionary recall. No other RITZ products or Mondelēz Global LLC products are affected, and in a huge relief, there have been zero reports of injury or illness linked to it. The recall was initiated after Mondelēz Global LLC discovered that film packaging rolls used for individually wrapped peanut butter products may have defects due to a supplier error. According to the notice, 'corrective actions are being taken to help ensure this issue does not recur.'
Just to be clear, cartons with only RITZ Cheese Cracker Sandwiches are not part of this recall. And if your RITZ Peanut Butter or RITZ Filled Cracker Sandwich Variety Pack has a different 'Best When Used By' date or plant code than the ones listed here, you're safe.
If you have a peanut allergy, it's recommended to discard any of the affected products immediately or return them to the place of purchase for a refund. You can call the company anytime at 1-844-366-1171, or reach a Consumer Relations specialist Monday through Friday, 9 am to 6 pm ET.Ritz Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know first appeared on Parade on Jul 9, 2025
This story was originally reported by Parade on Jul 9, 2025, where it first appeared.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

F.D.A. Panel to Reassess Hormone Therapy Warnings
F.D.A. Panel to Reassess Hormone Therapy Warnings

New York Times

time14 minutes ago

  • New York Times

F.D.A. Panel to Reassess Hormone Therapy Warnings

Dr. Marty Makary, commissioner of the Food and Drug Administration, will convene an expert panel on Thursday that he said will 'set the record straight' about hormone therapy for menopause, a treatment that he champions despite mixed findings about its risks and benefits. Although there is no public agenda, the panel is expected to discuss whether the risks have been overstated, deterring women who might benefit. All menopause treatments containing the hormone estrogen carry a black box warning that the medication should not be used to prevent cardiovascular disease or dementia, and that it increases the risk of strokes, blood clots and probable dementia. The label also warns of the possibility of breast cancer. But proponents like Dr. Makary say there's evidence that hormone therapy — approved for the treatment of symptoms like hot flashes — may prevent cognitive decline, heart disease and some cancers, in addition to conferring benefits that are not in dispute, like reducing osteoporosis-related fractures. Dr. Makary has dismissed findings of a heightened risk of breast cancer in women who took combined estrogen and progestin, saying the research caused a 'breast cancer scare' that has deterred women from getting a useful treatment. 'There's probably no medication that improves the health outcomes of a population more than hormone replacement therapy for women who start it within 10 years of the onset of menopause,' except perhaps antibiotics, Dr. Makary said on a podcast. Want all of The Times? Subscribe.

Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo
Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo

Yahoo

time4 hours ago

  • Yahoo

Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo

We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of Monday's top performers. Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working with Novo Nordisk in the future despite the termination of its earlier partnership. Novo Nordisk, maker of blockbuster drugs Wegovy and Ozempic, terminated its deal with Hims & Hers Health, Inc. (NYSE:HIMS) in June over allegations that the latter failed to adhere to federal laws that prohibit mass sales of compounded drugs under the false guise of 'personalization.' Hims & Hers Health, Inc. (NYSE:HIMS) has been selling knockoff versions of the drugs for years amid strong demand, but was this year ordered by the Food and Drug Administration (FDA) to stop due to a now sufficient supply. A nurse in a telehealth platform talking with a patient on video call for consultation. After the termination, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum said he was upset that Novo Nordisk felt the pressure over the knockoff version, but said that there was 'no way in hell we're going to cave on that.' Based on its historical reporting dates, Hims & Hers Health, Inc. (NYSE:HIMS) will report its earnings results for the second quarter in the first week of August 2025. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Stop Gas Station Heroin Coalition Commends FDA Crackdown on Illegal Drug '7'
Stop Gas Station Heroin Coalition Commends FDA Crackdown on Illegal Drug '7'

Associated Press

time5 hours ago

  • Associated Press

Stop Gas Station Heroin Coalition Commends FDA Crackdown on Illegal Drug '7'

Agency enforcement targets lab-made analogs, protecting consumers from unapproved new drugs The Stop Gas Station Heroin coalition today commended the U.S. Food and Drug Administration (FDA) for issuing warning letters to companies marketing '7" — a dangerous semi-synthetic alkaloid often disguised as a natural dietary supplement. This action marks a critical step toward curbing the spread of " Gas Station Heroin " — a term used to describe a range of often imported lab-made substances that include tianeptine, nitrous oxide, semi-synthetic and synthetic alkaloid products, and intoxicating hemp products. 7-hydroxymitragynine (7-OH) is only naturally present in trace amounts in dried kratom leaves. Bad actors synthetically mass produce high-concentration, ultra-potent 7-OH isolates in tablets, capsules, powders, and gummies. These chemically manipulated products are misleadingly marketed as natural dietary supplements or food. In reality, they act like prescription opioids and not botanicals, posing serious health risks such as respiratory depression, addiction, and overdose. The FDA's warning letters underscore what scientists and public health experts have long known: Gas Station Heroin products are not supplements. They are unapproved, mislabeled street drugs designed to mimic the effects of opioids and other narcotics. As the FDA notes, Gas Station Heroin products are often aggressively advertised online and in retail locations with deceptive claims about their safety and effectiveness, particularly to individuals seeking to get high or prescription alternatives for pain relief, anxiety, or opioid withdrawal. Stop Gas Station Heroin applauds the FDA for using its enforcement authority to hold these illicit companies accountable and to protect American consumers from the growing threat posed by synthetic drugs. About Stop Gas Station Heroin Stop Gas Station Heroin is a national coalition that aims to educate consumers about harmful synthetic drugs and advocate for smart regulation that distinguishes between legitimate, natural botanicals and dangerous, synthetic drugs, combined with enforcement of current federal laws around unapproved drugs. To learn more, navigate to Media Contact Colby Wilson [email protected] ### SOURCE: Stop Gas Station Heroin Copyright 2025 EZ Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store